STABILITECH BIOPHARMA LTD (“Stabilitech”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals, is pleased to announce an exclusive, worldwide license agreement with Oncolys BioPharma Inc. (“Oncolys”) of Japan. The in-licensing deal will explore the use of Stabilitech’s proprietary virus stability platform technology, Therm-SB™, to support Oncolys’ viroimmunotherapy pipeline led by Telomelysin®

Stabilitech will grant Oncolys a license in relation to Therm-SB, in return for which it will be entitled to receive undisclosed milestone fees and royalties according to development stages and sales performances. Oncolys aims to utilise the Therm-SB thermostability technology to improve the usability of its existing oncolytic virus pipeline, in response to demand in clinical settings, and expects to apply the platform to next generation candidates currently under development for systemic treatment.

“We are delighted to partner with an international business of Oncolys’ stature to demonstrate further the strength and versatility of Therm-SB, this time in cancer treatment.”said Stabilitech CEO, Wayne Channon. “Our companies share a mission to bring innovation and technology to existing treatments for serious conditions with unmet needs and we are confident that our relationship will be fruitful.”

Therm-SB has been applied successfully to a number of biopharmaceuticals and other temperature labile biological materials. The platform is based on a formulation of non-toxic small molecules that are mixed with the virus/vaccine during the fill-finish process.

“Our Therm-SB platform will change the way virotherapy products are stored and handled. No more cold-chain logistics for manufacturers, or product wastage for temperature excursions within hospitals.,” said Elliot Bland, Ph.D., Business Development Director at Stabilitech. “We have seen success with Therm-SB on all viruses to date: vaccines, gene therapy vectors and virotherapies.We look forward to continuing that success with Telomelysinand others in the Oncolys pipeline.”